Changchun Hi-Tech (000661.SZ): Injectable fuchibizumab approved for marketing in China

Zhitongcaijing · 07/02 13:33

Zhitong Finance App News, Changchun Hi-Tech (000661.SZ) issued an announcement. Recently, the company learned from the website of the State Drug Administration that the injectable fuxinqibizumab declared by the holding subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as “Jinsai Pharmaceutical”) has been approved for marketing by the State Drug Administration.

According to reports, injectable fuchibimab is a novel all-human anti-IL-1beta monoclonal antibody drug developed by the company. It is a new class 1 drug for therapeutic biological products. It can specifically bind human IL-1β to block the production of inflammatory mediators induced by IL-1beta, and is used in adult patients with acute attacks of gout arthritis.